Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program and Expand Use of Innovative Dendritic Cell Platform for Studies in Other Indications

▤ Summary

Diakonos Oncology closed a $20 million SAFE financing to advance its Phase 2 glioblastoma program for dubodencel and expand work into other cancer indications. The company said the capital will help fund clinical development and act as a bridge toward a Series A round planned for the second half of the year. New backers include Baylor College of Medicine, the Brain Tumor Investment Fund, and the Buttonwood Titan QC Fund, alongside participation from existing shareholders. The company also highlighted encouraging early clinical and preclinical data for its dendritic cell therapy platform in glioblastoma and pancreatic cancer.

$ Funding

▦ Linked Companies